Historical salary details - Mr. Gary A. Lyons, Chairman of the Board, Travere Therapeutics Inc
Mr. Gary A. Lyons is the Chairman of the Board of Travere Therapeutics Inc. They also hold 2 other positions in Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals.
Mr. Gary A. Lyons
Chairman of the Board
$ 262.3 K
Gross Remuneration
-
Current Company
Travere Therapeutics Inc
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Travere Therapeutics Inc | Chairman of the Board | 262.3 K | - |
| 2024 | Neurocrine Biosciences, Inc. | Independent Director | - | - |
| 2024 | Rigel Pharmaceuticals | Independent Director | - | - |
| 2023 | Neurocrine Biosciences, Inc. | Independent Director | 460.1 K | 0.0 % |
| 2023 | Eledon Pharmaceuticals Inc | Independent Director | 337.7 K | - |
| 2023 | Rigel Pharmaceuticals | - | 113.6 K | -26.7 % |
| 2023 | Fresh Tracks Therapeutics Inc | Independent Director | - | - |
| 2023 | Travere Therapeutics Inc | Chairman of the Board | - | - |
| 2022 | Neurocrine Biosciences, Inc. | Independent Director | 460.0 K | 0.0 % |
| 2022 | Travere Therapeutics Inc | Chairman of the Board | 345.9 K | 12.8 % |
| 2022 | Rigel Pharmaceuticals | Independent Director | 154.9 K | -42.3 % |
| 2022 | Fresh Tracks Therapeutics Inc | Independent Director | 76.9 K | -18.5 % |
| 2022 | Eledon Pharmaceuticals Inc | Independent Director | - | - |
| 2021 | Neurocrine Biosciences, Inc. | Independent Director | 460.0 K | 0.4 % |
| 2021 | Travere Therapeutics Inc | Chairman of the Board | 306.7 K | 12.5 % |
| 2021 | Rigel Pharmaceuticals | Independent Director | 268.4 K | 60.1 % |
| 2021 | Fresh Tracks Therapeutics Inc | Independent Director | 94.4 K | 1.2 % |
| 2021 | Eledon Pharmaceuticals Inc | Independent Director | 65 K | -87.0 % |
| 2020 | Eledon Pharmaceuticals Inc | Independent Director | 498.6 K | 612.9 % |
| 2020 | Neurocrine Biosciences, Inc. | Independent Director | 458.3 K | -9.6 % |
| 2020 | Travere Therapeutics Inc | Chairman of the Board | 272.7 K | 2.6 % |
| 2020 | Rigel Pharmaceuticals | Chairman of the Board | 167.7 K | -5.1 % |
| 2020 | Fresh Tracks Therapeutics Inc | Independent Director | 93.2 K | 382.1 % |
| 2019 | Neurocrine Biosciences, Inc. | Independent Director | 507.1 K | -28.9 % |
| 2019 | Travere Therapeutics Inc | Chairman of the Board | 265.7 K | -35.8 % |
| 2019 | Rigel Pharmaceuticals | Chairman of the Board | 176.8 K | -15.3 % |
| 2019 | Eledon Pharmaceuticals Inc | Independent Director | 69.9 K | -22.8 % |
| 2019 | Fresh Tracks Therapeutics Inc | Independent Director | 19.3 K | - |
| 2019 | Plus Therapeutics Inc | - | 942.0 | -97.8 % |
| 2019 | Plus Therapeutics Inc | Independent Director | - | - |
| 2018 | Neurocrine Biosciences, Inc. | Independent Director | 712.8 K | 43.1 % |
| 2018 | Travere Therapeutics Inc | Chairman of the Board | 414 K | 69.1 % |
| 2018 | Rigel Pharmaceuticals | Chairman of the Board | 208.7 K | 20.1 % |
| 2018 | Eledon Pharmaceuticals Inc | Independent Director | 90.6 K | -11.8 % |
| 2018 | Plus Therapeutics Inc | Independent Director | 42.5 K | -41.2 % |
| 2018 | Fresh Tracks Therapeutics Inc | Independent Director | - | - |
| 2017 | Neurocrine Biosciences, Inc. | Independent Director | 498.0 K | 9.0 % |
| 2017 | Travere Therapeutics Inc | Chairman of the Board | 244.8 K | 27.4 % |
| 2017 | Rigel Pharmaceuticals | Chairman of the Board | 173.7 K | 10.5 % |
| 2017 | Eledon Pharmaceuticals Inc | Independent Director | 102.8 K | - |
| 2017 | Plus Therapeutics Inc | Independent Director | 72.3 K | 3.2 % |
| 2017 | Fresh Tracks Therapeutics Inc | Independent Director | 68.3 K | -5.2 % |
| 2016 | Neurocrine Biosciences, Inc. | Independent Director | 457.0 K | -39.6 % |
| 2016 | Travere Therapeutics Inc | Independent Director | 192.2 K | -41.7 % |
| 2016 | Rigel Pharmaceuticals | Lead Independent Director and Chairman of the Boar | 157.1 K | -41.5 % |
| 2016 | Fresh Tracks Therapeutics Inc | Independent Director | 72.1 K | -19.3 % |
| 2016 | Plus Therapeutics Inc | Independent Director | 70.1 K | 33.7 % |
| 2016 | Eledon Pharmaceuticals Inc | Independent Director | - | - |
| 2015 | Neurocrine Biosciences, Inc. | Independent Director | 757.2 K | 298.5 % |
| 2015 | Travere Therapeutics Inc | Independent Director | 329.3 K | -36.3 % |
| 2015 | Rigel Pharmaceuticals | Lead Independent Director and Chairman of the Boar | 268.7 K | 63.5 % |
| 2015 | Fresh Tracks Therapeutics Inc | Independent Director | 89.3 K | -9.2 % |
| 2015 | Plus Therapeutics Inc | Independent Director | 52.4 K | 18.8 % |
| 2014 | Travere Therapeutics Inc | Independent Director | 517.4 K | - |
| 2014 | Neurocrine Biosciences, Inc. | Independent Director | 190 K | 3.5 % |
| 2014 | Rigel Pharmaceuticals | Lead Independent Director and Chairman of the Boar | 164.3 K | 41.1 % |
| 2014 | Fresh Tracks Therapeutics Inc | Independent Director | 98.3 K | -58.3 % |
| 2014 | Plus Therapeutics Inc | Independent Director | 44.1 K | -50.6 % |
| 2013 | Fresh Tracks Therapeutics Inc | Independent Director | 236 K | 5.0 % |
| 2013 | Neurocrine Biosciences, Inc. | Independent Director | 183.6 K | 57.1 % |
| 2013 | Rigel Pharmaceuticals | Lead Independent Director | 116.5 K | -17.8 % |
| 2013 | Plus Therapeutics Inc | Independent Director | 89.2 K | - |
| 2013 | Travere Therapeutics Inc | Director | - | - |
| 2012 | Fresh Tracks Therapeutics Inc | Independent Director | 224.7 K | -24.2 % |
| 2012 | Rigel Pharmaceuticals | Independent Director | 141.8 K | -7.1 % |
| 2012 | Neurocrine Biosciences, Inc. | Independent Director | 116.9 K | -1.8 % |
| 2011 | Fresh Tracks Therapeutics Inc | Independent Director | 296.4 K | 38.3 % |
| 2011 | Rigel Pharmaceuticals | Independent Director | 152.5 K | 23.1 % |
| 2011 | Neurocrine Biosciences, Inc. | Independent Director | 119.0 K | -60.3 % |
| 2010 | Neurocrine Biosciences, Inc. | Independent Director | 299.8 K | -86.7 % |
| 2010 | Fresh Tracks Therapeutics Inc | Independent Director | 214.3 K | 101.8 % |
| 2010 | Rigel Pharmaceuticals | Independent Director | 123.9 K | 16.7 % |
| 2009 | Neurocrine Biosciences, Inc. | Director | 2.3 M | 3654.8 % |
| 2009 | Rigel Pharmaceuticals | Director | 106.2 K | -50.5 % |
| 2009 | Fresh Tracks Therapeutics Inc | Director | 106.2 K | 75.8 % |
| 2008 | Rigel Pharmaceuticals | Director | 214.5 K | 39.6 % |
| 2008 | Fresh Tracks Therapeutics Inc | Director | 60.4 K | -10.1 % |
| 2008 | Neurocrine Biosciences, Inc. | Director | 60.1 K | - |
| 2007 | Rigel Pharmaceuticals | Director | 153.7 K | -11.6 % |
| 2007 | Fresh Tracks Therapeutics Inc | Director | 67.2 K | -3.8 % |
| 2007 | Neurocrine Biosciences, Inc. | Director | - | - |
| 2006 | Rigel Pharmaceuticals | Director | 173.9 K | 4748.2 % |
| 2006 | Fresh Tracks Therapeutics Inc | Director | 69.8 K | - |
| 2006 | Neurocrine Biosciences, Inc. | President, Chief Executive Officer and Director | - | - |
| 2005 | Rigel Pharmaceuticals | Director | 3.6 K | - |
| 2005 | Fresh Tracks Therapeutics Inc | Director | - | - |
| 2005 | Neurocrine Biosciences, Inc. | President, Chief Executive Officer and Director | - | - |
| 2004 | Neurocrine Biosciences, Inc. | President, Chief Executive Officer and Director | - | - |
| 2004 | Rigel Pharmaceuticals | Director | - | - |
| 2004 | Fresh Tracks Therapeutics Inc | Director | - | - |
| 2003 | Neurocrine Biosciences, Inc. | President, Chief Executive Officer and Director | - | - |
| 2003 | Fresh Tracks Therapeutics Inc | Director | - | - |
| 2002 | Neurocrine Biosciences, Inc. | President, Chief Executive Officer and Director | - | - |
| 2002 | Fresh Tracks Therapeutics Inc | Director | - | - |
| 2001 | Neurocrine Biosciences, Inc. | President, Chief Executive Officer and Director | - | - |
| 2001 | Fresh Tracks Therapeutics Inc | Director | - | - |
| 2000 | Neurocrine Biosciences, Inc. | President, Chief Executive Officer and Director | - | - |
| 2000 | Fresh Tracks Therapeutics Inc | Director | - | - |